You have entered the IISP: Interactive Information System on Pathogenomics
If you would like to insert information about your research or research group, please click to the following link to download the form. After filling it out, please send back to email@example.com or firstname.lastname@example.org.
Here you will find information about Research groups in the PathoGenoMics fields from the ERA-NET partner countries (Austria, Finland, France, Hungary, Israel, Latvia, Portugal, Slovenia and Spain).
This information is supposed to support cooperation between researchers from different European countries
and thus enhance the development of a European Research Area for PathoGenoMics .
The following information is available and can be searched for:
- researcher names
- Institution of the respective researcher, city and country of his/her institution
- Contact data of the researcher (address, phone, email)
- Research topics and studied microorganisms of the researcher
- Special techniques applied by the researcher
- Potential cooperation topics suggested by the researcher
If you have any comments/questions or if you would like to add some information, please contact email@example.com
|Name:||Prof. Dr. Gonzales de la Campa, Adela|
|Address:||Ctra.Majadahonda a Pozuelo, km. 2,2|
|Institution:||Centro national de Microbiologia, Instituto de Salud Carlos III|
|Molecular bases of antimicrobial susceptibility of Streptococcus pneumoniae and viridans group streptococci (VS): 1. Amino alcohol antimalarial drugs, such as optochin, quinine, mefloquine. The optochin susceptibility test is routinely used in the clinical laboratories for the differentiation of S. pneumoniae and VS. Amino alcohol antimalarial drugs target the c and a subunits of the F0 complex of the F0F1 H+-ATPase [1-4]. S. pneumoniae could be used as a model system to test the activity of new antimalarial drugs, and, on the other hand, given that the F0F1-ATPase is essential for cell viability , it is also an appropriate target for the development of new antimicrobial drugs . The F0F1-ATPase creates a transmembranal proton gradient and control the intracellular pH, its expression being regulated at the level of initiation of transcription . 2. Fluoroquinolones (Fq). We have characterized the pneumococcal genes encoding the intracellular targets of Fq: DNA topoisomerase IV and DNA gyrase enzymes [7-9], and demonstrated at the genetic  and biochemical level  that DNA topoisomerase IV is a primary target for most Fqs, being DNA gyrase a secondary target. SV share the same mechanism of Fq resistance  and are acting as a reservoir of Fq resistance. We have described the emergence of Fq resistance in S. pneumoniae   and detected several Fq-resistant isolates carrying recombinant DNA topoisomerase genes . A different gene organization of the DNA topoisomerase IV genes in these recombinant strains and in VS (parE-.ant-parC) when compared with non-recombinant S. pneumoniae isolates (parE-parC) is an evidence that VS are acting as DNA donors . Recent investigations have shown that Fq-resistant S. pneumoniae are being selected among isolates of the major epidemic multi-resistant clones, including recombinant strains . On the other hand, our group has described the presence of Fq efflux pumps in S. pneumoniae  and in VS .|
|Special methods / technologies:|
|Suggestions for potential research cooperations:|
|Characterization of \\\"atypical\\\" S. pneumoniae strains
Clonal structure of fluoroquinolone-resistant S. pneumoniae strains
Genomic studies on the acid tolerance response of S. pneumoniae